Creative Medical Technology Holdings, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $6.7M
- Price
- $0.889
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.27%
- Volume
- 52.2K
About
Creative Medical Technology Holdings, Inc., a biotechnology firm based in Phoenix, Arizona, specializes in advancing adult stem cell treatments. The company's core focus spans several medical fields, including immunology, urology, orthopedics, and neurology. Among its therapeutic offerings are CaverStem, designed to address erectile dysfunction; FemCelz, which aims to restore genital sensitivity and alleviate dryness; StemSpine, developed to treat chronic lower back pain; ImmCelz, intended for stroke patients; and OvaStem, a solution for female infertility.
Quick stats
Shares outstanding7.6M
Computed float5.6M
Float / shares73.2%
Cash runway (months)14.1
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001187953
AI Summary
AI-generated1/12
minorbullishoperations update
Creative Medical Technology Holdings, Inc. Expands Ultrasome™ Intellectual Property Portfolio with New U.S. Provisional Patent Filing
Creative Medical Technology Holdings (NASDAQ: CELZ) filed a new U.S. provisional patent application to broaden intellectual property protection around Ultrasome, its proprietary cell-free regenerative medicine platform.
The filing seeks coverage across product composition, biological potency, manufacturing and quality control, stability, delivery methods and therapeutic applications, and builds on an April 2026 pilot study in which approximately 93% of knee osteoarthritis participants showed clinically meaningful improvement with no serious adverse events.
Caveats are explicit: the provisional application has not been examined by the USPTO, there is no assurance any patent issues, and the FDA Drug Master File covering the underlying Olastrocel cell bank does not itself constitute regulatory approval.
Red flags
- provisional patent application is unexamined by USPTO with no assurance of issuance or claim scope
- additional indications beyond osteoarthritis are in early R&D with no evidence of clinical efficacy or regulatory approval
- Drug Master File with FDA does not constitute approval, clearance or authorization
- clinical-stage micro-cap with financing risk cited in forward-looking statements